Advertisement

Organisation › Details
Wellington Partners (Group)
https://www.wellington-partners.com
Twitter: @wellingtonvc
LinkedIn: https://www.linkedin.com/company/wellington-partners
Wellington Partners is a leading European Venture Capital firm investing in early- and growth stage life science companies. Wellington Partners is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totalling EUR 1.0 billion, and more than EUR 400 million committed to Life Sciences, Wellington Partners has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, Wellington Partners has invested in 46 innovative life science companies, including Actelion (acquired by J&J), Definiens (acquired by AZ/Medimmune), Invendo (acquired by Ambu), MTM laboratories (acquired by Roche), Rigontec (acquired by MSD), Symetis (acquired by Boston Scientific), Immatics and AMBOSS. *
![]() |
Start | 1998-01-01 established |
Today | Wellington Partners Venture Capital GmbH | |
![]() |
Industry | venture capital |
Industry 2 | LIFE SCIENCES | |
![]() |
Person | Strohmenger, Rainer (Wellington Partners Venture Capital 201303 General Partner) |
Person 2 | Essig, Stuart M. (Wellington Partners 201303– Venture Partner before Integra Life Sciences CEO + Goldman Sachs) | |
![]() |
Region | München (Munich) |
Country | Germany | |
Street | 5 Türkenstr. | |
City | 80333 München | |
Tel | +49-89-219941-0 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Annual sales | 1,000,000,000 (capital under management (2018) 2018-11-26) | |
* Document for �About Section�: Wellington Partners. (7/31/19). "Press Release: Wellington Partners Raises EUR 210 Million Life Science Fund". | ||
Record changed: 2021-02-21 |
Advertisement

More documents for Wellington Partners (Group)
- [1] Adrenomed AG. (1/4/21). "Press Release: Adrenomed Supervisory Board Appoints Dr. Wolfgang Baiker as CEO". Hennigsdorf....
- [2] Adrenomed AG. (11/30/20). "Press Release: Adrenomed Closes EUR 22 Million Equity Financing to Accelerate Development of Adrecizumab (HAM8101) and Provides Business Update". Hennigsdorf....
- [3] NBE Therapeutics AG. (8/10/20). "Press Release: NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors". Basel....
- [4] Wellington Partners. (1/8/20). "Press Release: Karl Naegler Joins Wellington Partners as Managing Partner". Munich....
- [5] Wellington Partners. (7/31/19). "Press Release: Wellington Partners Raises EUR 210 Million Life Science Fund"....
- [6] Confo Therapeutics N.V.. (5/7/19). "Press Release: Confo Therapeutics Raises €30 Million in Series A Financing". Ghent....
- [7] Snipr Biome ApS. (3/11/19). "Press Release: Snipr Biome Raises $50 Million Series A Financing to Advance CRISPR-based Microbiome Drugs to Human Clinical Trials". Copenhagen....
- [8] CMS Hasche Sigle. (12/3/18). "Press Release: CMS berät Wellington und HBM als Lead Investoren der Serie D-Finanzierungsrunde der Adrenomed". München....
- [9] Themis Bioscience GmbH. (11/28/16). "Press Release: Themis Bioscience Successfully Closes 10 M EUR Financing Round". Vienna....
- [10] UroMems. (11/15/16). "Press Release: UroMems Closes €14m Financing to Develop Its Smart Artificial Urinary Sphincter to Market". Grenoble....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top